Announced Wed, 23 Sept, 2026 · 17:07 IST
Concord Biotech approves 1:1 bonus issue and doubles authorised capital
CONCORDBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-7.0%1-day move
₹1563.00
prior close
₹1548.50
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.8-3.0-3.9-2.8-7.0-10.7-9.9-12.3-10.5-12.2————
Up moveDown movePending
AI summary
Board approved bonus shares in 1:1 ratio (1 bonus share for every 1 held), issuing about 10.46 crore equity shares of Rs. 1 each. Funded from share premium account (Rs. 81.97 crore available as on March 31, 2026). Authorised share capital doubled from Rs. 11 crore to Rs. 22 crore. Pre-bonus paid-up capital Rs. 10.46 crore rises to Rs. 20.92 crore. Record date to be decided; shares to be credited by November 22, 2026. Subject to shareholder approval.
Likely market impact
Share count doubles so price will adjust lower proportionally. Increases liquidity and signals confidence from management. Await record date.